uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Clinical diabetology and metabolism.ORCID iD: 0000-0001-5498-3899
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Clinical diabetology and metabolism.ORCID iD: 0000-0002-2639-9481
2019 (English)In: Drugs, ISSN 0012-6667, E-ISSN 1179-1950, Vol. 79, no 3, p. 219-230Article in journal (Refereed) Published
Abstract [en]

Sodium-glucose co-transporter 2 (SGLT2) inhibitors are glucose-lowering drugs that reduce plasma glucose levels by inhibiting glucose and sodium reabsorption in the kidneys, thus resulting in glucosuria. Their effects consequently include reductions in HbA1c, blood glucose levels, and blood pressure, but also reductions in body weight and adiposity. The ability to reduce body weight is consistently observed in individuals taking SGLT2 inhibitors, but this weight loss is moderate due to counter-regulatory mechanisms striving to maintain body weight. This has prompted exploration of SGLT2 inhibitors in combination with other agents acting via decreased food intake, e.g., glucagon-like peptide 1 receptor agonists (GLP1-RAs). The bodyweight effects are promising, and together with the signs of prevention of cardiovascular and renal events, such combinations including SGLT2 inhibitors are appealing. The weight loss is clinically important, as most individuals with type 2 diabetes are overweight or obese, but also because there is an unmet need for safe, effective, and durable weight loss interventions in obese individuals without diabetes.

Place, publisher, year, edition, pages
ADIS INT LTD , 2019. Vol. 79, no 3, p. 219-230
National Category
Endocrinology and Diabetes
Identifiers
URN: urn:nbn:se:uu:diva-379267DOI: 10.1007/s40265-019-1057-0ISI: 000459785400001PubMedID: 30701480OAI: oai:DiVA.org:uu-379267DiVA, id: diva2:1296898
Funder
Swedish Diabetes AssociationEXODIAB - Excellence of Diabetes Research in SwedenErnfors FoundationAstraZenecaAvailable from: 2019-03-18 Created: 2019-03-18 Last updated: 2019-03-18Bibliographically approved

Open Access in DiVA

fulltext(836 kB)74 downloads
File information
File name FULLTEXT01.pdfFile size 836 kBChecksum SHA-512
7988613b5a00af7ea7cfd21a6db4ff339aa0da03be5fc33599c5a45696c1cf915957e60c085bfe68600c9d5de5acb6539600558cd75dcf1ba23ff4c1500e39b5
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records BETA

Pereira, Maria JEriksson, Jan

Search in DiVA

By author/editor
Pereira, Maria JEriksson, Jan
By organisation
Clinical diabetology and metabolism
In the same journal
Drugs
Endocrinology and Diabetes

Search outside of DiVA

GoogleGoogle Scholar
Total: 74 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 54 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf